• DOI:10.1097/CJI.0b013e3182048c4e
Corpus ID: 26385818

Possibility of Adoptive Immunotherapy With Peripheral Blood-derived CD3−CD56+ and CD3+CD56+ Cells for Inducing Antihepatocellular Carcinoma and Antihepatitis C Virus Activity

@article{Doskali2011PossibilityOA,
  title={Possibility of Adoptive Immunotherapy With Peripheral Blood-derived CD3−CD56+ and CD3+CD56+ Cells for Inducing Antihepatocellular Carcinoma and Antihepatitis C Virus Activity},
  author={M. Doskali and Y. Tanaka and M. Ohira and K. Ishiyama and H. Tashiro and K. Chayama and H. Ohdan},
  journal={Journal of Immunotherapy},
  year={2011},
  volume={34},
  pages={129–138}
}

M. Doskali, Y. Tanaka, +4 authors H. Ohdan

Published 2011

Biology, Medicine

Journal of Immunotherapy

We recently showed that interleukin (IL)-2-stimulated CD56+ cells derived from the liver exert vigorous cytotoxicity against hepatocellular carcinoma (HCC) by their binding to the tumor necrosis factor-related apoptosis-inducing ligand expressed on natural killer cells and the corresponding death receptors, and exhibit inhibitory effects on hepatitis C virus (HCV) replication by production of a high level of interferon-&ggr;. These findings prompted us to develop a technique to increase the… CONTINUE READING

View on Wolters Kluwer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed